AtriCure Inc
ATRC36.350USD
+1.940+5.64%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
1.81BMarket Cap
LossP/E TTM
More Details of AtriCure Inc Company
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
Company Info
Ticker SymbolATRC
Company nameAtriCure Inc
IPO dateAug 05, 2005
CEOMr. Michael H. (Mike) Carrel, CPA
Number of employees1300
Security typeOrdinary Share
Fiscal year-endAug 05
Address7555 Innovation Way
CityMASON
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code45040
Phone15137554100
Websitehttps://www.atricure.com
Ticker SymbolATRC
IPO dateAug 05, 2005
CEOMr. Michael H. (Mike) Carrel, CPA
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Michael H. (Mike) Carrel, CPA
Mr. Michael H. (Mike) Carrel, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
718.94K
+0.11%
Mr. Salvatore Privitera, J.D.
Mr. Salvatore Privitera, J.D.
Chief Technical Officer
Chief Technical Officer
125.59K
+0.66%
Mr. Robert S. (Bob) White
Mr. Robert S. (Bob) White
Independent Chairman of the Board
Independent Chairman of the Board
92.17K
+20.06%
Mr. Justin J. Noznesky
Mr. Justin J. Noznesky
Chief Marketing and Strategy Officer
Chief Marketing and Strategy Officer
86.96K
+23.01%
Dr. Vinayak Doraiswamy, Ph.D.
Dr. Vinayak Doraiswamy, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.37K
+1.12%
Mr. Karl S. Dahlquist, J.D.
Mr. Karl S. Dahlquist, J.D.
Chief Legal Officer
Chief Legal Officer
68.55K
+1.21%
Ms. Regina E. (Reggie) Groves
Ms. Regina E. (Reggie) Groves
Independent Director
Independent Director
36.17K
+17.56%
Mr. Sven A. Wehrwein, CPA
Mr. Sven A. Wehrwein, CPA
Independent Director
Independent Director
34.37K
+18.64%
Ms. Deborah H. (Deb) Telman
Ms. Deborah H. (Deb) Telman
Independent Director
Independent Director
22.18K
+32.18%
Mr. Shlomo Nachman
Mr. Shlomo Nachman
Independent Director
Independent Director
18.51K
+41.20%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael H. (Mike) Carrel, CPA
Mr. Michael H. (Mike) Carrel, CPA
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
718.94K
+0.11%
Mr. Salvatore Privitera, J.D.
Mr. Salvatore Privitera, J.D.
Chief Technical Officer
Chief Technical Officer
125.59K
+0.66%
Mr. Robert S. (Bob) White
Mr. Robert S. (Bob) White
Independent Chairman of the Board
Independent Chairman of the Board
92.17K
+20.06%
Mr. Justin J. Noznesky
Mr. Justin J. Noznesky
Chief Marketing and Strategy Officer
Chief Marketing and Strategy Officer
86.96K
+23.01%
Dr. Vinayak Doraiswamy, Ph.D.
Dr. Vinayak Doraiswamy, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
74.37K
+1.12%
Mr. Karl S. Dahlquist, J.D.
Mr. Karl S. Dahlquist, J.D.
Chief Legal Officer
Chief Legal Officer
68.55K
+1.21%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Appendage Management-United states
42.09M
34.05%
Open Ablation - United states
33.31M
26.94%
Pain management
17.27M
13.97%
Appendage management -International
9.67M
7.83%
Open ablation -International
8.99M
7.28%
Other
12.28M
9.94%
By RegionUSD
Name
Revenue
Proportion
United States
101.15M
81.82%
Europe
14.20M
11.49%
Asia
6.78M
5.49%
Other international
1.49M
1.20%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Appendage Management-United states
42.09M
34.05%
Open Ablation - United states
33.31M
26.94%
Pain management
17.27M
13.97%
Appendage management -International
9.67M
7.83%
Open ablation -International
8.99M
7.28%
Other
12.28M
9.94%
Shareholding Stats
Updated: Tue, May 20
Updated: Tue, May 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.46%
AllianceBernstein L.P.
7.40%
BlackRock Institutional Trust Company, N.A.
7.19%
Hood River Capital Management LLC
6.03%
Macquarie Investment Management
4.90%
Other
65.02%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.46%
AllianceBernstein L.P.
7.40%
BlackRock Institutional Trust Company, N.A.
7.19%
Hood River Capital Management LLC
6.03%
Macquarie Investment Management
4.90%
Other
65.02%
Shareholder Types
Shareholders
Proportion
Investment Advisor
56.65%
Investment Advisor/Hedge Fund
33.71%
Hedge Fund
10.66%
Individual Investor
3.55%
Research Firm
1.93%
Pension Fund
0.75%
Bank and Trust
0.50%
Sovereign Wealth Fund
0.23%
Family Office
0.07%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
531
53.52M
108.11%
-4.10M
2025Q1
544
53.44M
107.95%
-4.07M
2024Q4
526
50.00M
102.31%
-11.07M
2024Q3
522
53.78M
110.47%
-8.64M
2024Q2
511
54.11M
111.85%
-4.03M
2024Q1
517
53.02M
109.65%
-1.47M
2023Q4
515
50.20M
105.93%
-1.70M
2023Q3
504
48.87M
103.22%
-3.82M
2023Q2
499
48.88M
103.48%
-3.46M
2023Q1
503
48.62M
102.63%
-1.48M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
4.70M
9.5%
+61.17K
+1.32%
Mar 31, 2025
AllianceBernstein L.P.
3.68M
7.43%
-158.60K
-4.14%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.57M
7.21%
-92.41K
-2.52%
Mar 31, 2025
Hood River Capital Management LLC
3.00M
6.06%
+75.48K
+2.58%
Mar 31, 2025
Macquarie Investment Management
2.44M
4.92%
+61.60K
+2.59%
Mar 31, 2025
Champlain Investment Partners, LLC
2.14M
4.32%
-390.65K
-15.45%
Mar 31, 2025
Two Sigma Investments, LP
1.33M
2.68%
+75.83K
+6.06%
Mar 31, 2025
First Light Asset Management, LLC
1.31M
2.66%
-654.50K
-33.24%
Mar 31, 2025
State Street Global Advisors (US)
1.28M
2.58%
-68.53K
-5.09%
Mar 31, 2025
UBS Asset Management (Switzerland)
1.26M
2.54%
+537.08K
+74.31%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
SPDR S&P Health Care Equipment ETF
1.81%
Harbor Human Capital Factor US Small Cap ETF
0.76%
NYLI Healthy Hearts ETF
0.47%
First Trust Small Cap Growth AlphaDEX Fund
0.45%
Invesco NASDAQ Future Gen 200 ETF
0.43%
Amplify Etho Climate Leadership U.S. ETF
0.3%
JPMorgan Fundamental Data Science Small Core ETF
0.26%
Franklin US Small Cap Multifactor Index ETF
0.25%
First Trust Small Cap Core Alphadex Fund
0.24%
iShares U.S. Medical Devices ETF
0.18%
View more
SPDR S&P Health Care Equipment ETF
Proportion1.81%
Harbor Human Capital Factor US Small Cap ETF
Proportion0.76%
NYLI Healthy Hearts ETF
Proportion0.47%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.45%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.43%
Amplify Etho Climate Leadership U.S. ETF
Proportion0.3%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.26%
Franklin US Small Cap Multifactor Index ETF
Proportion0.25%
First Trust Small Cap Core Alphadex Fund
Proportion0.24%
iShares U.S. Medical Devices ETF
Proportion0.18%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
